Quoin Pharmaceuticals
- Company typePublic
- Founded2021
- HeadquartersAshburn, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Quoin Pharmaceuticals does
Quoin Pharmaceuticals (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan skin diseases, headquartered in Ashburn, Virginia. Its pipeline comprises three distinct product candidates. The lead asset, QRX003 (proposed brand name QYLEKI), is a topical lotion containing a broad-spectrum serine protease inhibitor formulated with a proprietary polymer delivery technology licensed from Skinvisible's Invisicare system; the active ingredient functionally replaces the missing LEKTI protein in patients with SPINK5 gene mutations, down-regulating Kallikrein hyperactivity to normalize skin shedding and strengthen the skin barrier. QRX003 is in pivotal Phase 3 development for Netherton Syndrome, with additional INDs/plans for Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. QRX008 is a small-molecule VLA-4 inhibitor in early development for Scleroderma, with proof of concept demonstrated in the Tsk1/+ mouse model. QRX009 is a proprietary topical rapamycin formulation (4% lotion, 5% dermal patch) targeting Microcystic Lymphatic Malformations, Venous Malformations, and Angiofibromas, with planned investigator-led studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
Quoin Pharmaceuticals firmographics
Firmographics- Name
- Quoin Pharmaceuticals
- Legal name
- Quoin Pharmaceuticals, Inc.
- Website
- https://quoinpharma.com
- Company type
- Public
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Quoin Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals — Rare Disease Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industries
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Quoin Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Ashburn
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Quoin Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Product Sales (Future): Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company. It does not yet have approved products generating revenue. Its business model is premised on developing and commercializing therapeutic drug products for rare and orphan diseases, with the expectation of generating revenue through product sales upon regulatory approval. The company has received Orphan Drug Designation in the US, EU, and Japan for QRX003, which provides potential market exclusivity benefits upon approval.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Quoin Pharmaceuticals product offering
Product offeringCore offering
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing topical and small-molecule therapeutics for rare and orphan skin and connective tissue diseases. Its lead candidate QRX003 (QYLEKI) is a broad-spectrum serine protease inhibitor lotion in pivotal Phase 3 trials for Netherton Syndrome, with additional development in Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. The pipeline also includes QRX008 (a VLA-4 small-molecule inhibitor for Scleroderma) and QRX009 (a proprietary topical rapamycin lotion and dermal patch for vascular malformations and related skin disorders). None of these products are yet approved; commercial revenue is expected from future product sales supported by a mix of direct sales infrastructure and international distribution partnerships.
Product overview
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing therapeutic products for rare and orphan diseases. The company operates a pipeline of three distinct product candidates: QRX003 (QYLEKI), a topical serine protease inhibitor lotion for Netherton Syndrome and related skin disorders; QRX008, a VLA-4 inhibitor for Scleroderma; and QRX009, a topical rapamycin formulation for vascular and skin malformations. The company has established international marketing and distribution partnerships covering 61 countries and plans internal commercial infrastructure for the US, Western Europe, and Japan markets.
Differentiator
Problem solved
Functional benefit
Brands
- QYLEKI: Proposed brand name for investigational drug QRX003 for Netherton Syndrome
- NETHERTON NOW
Products and services
- QRX003 (proposed brand: QYLEKI) QRX003 is a topical lotion comprised of a broad-spectrum serine protease inhibitor formulated with proprietary delivery technology (Invisicare polymer delivery system licensed from Skinvisible, Inc.). The active ingredient performs the function of the missing LEKTI protein and down-regulates Kallikrein hyperactivity, leading to normalized skin shedding and a stronger skin barrier. The lead indication is Netherton Syndrome (a rare genetic skin disorder caused by SPINK5 mutations with a 10-20% newborn mortality rate and no approved treatment); additional indications include Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. It is being studied in pediatric and adult patients via two FDA-cleared pivotal whole-body clinical studies and an open IND.
- QRX008 QRX008 is a small-molecule VLA-4 inhibitor being developed for the treatment of Scleroderma (systemic sclerosis). It uses small-molecule inhibitors to disrupt the VCAM-1:VLA-4 interaction, a key process controlling immune cell migration into inflamed tissue. Proof of concept has been demonstrated with VLA-4 inhibition in the Tsk1/+ mouse model of Scleroderma.
- QRX009 QRX009 is a proprietary topical formulation of rapamycin (sirolimus) designed to optimize local skin penetration and deliver rapamycin directly to affected dermal layers. The company achieved target loadings of 4% rapamycin in its topical lotion and 5% in its dermal patch delivery systems. It is being developed for rare vascular and skin malformations including Microcystic Lymphatic Malformations, Venous Malformations, and Cutaneous Angiofibromas, with planned investigator-led clinical studies in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
Quantifiable outcome
- 4 out of 6 pediatric Netherton Syndrome patients (under 10 years of age) showed 'Improved' or 'Significantly Improved' status across key clinical endpoints
- +5 more outcomes
Companies that use Quoin Pharmaceuticals
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Quoin Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Quoin Pharmaceuticals partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Professor Edel O'Toole, Queen Mary University of LondoncoreProfessor Edel O'Toole of Queen Mary University of London is leading an investigator-initiated clinical study for QRX009 in Pachyonychia Congenita, planned for Q3 2026. This is one of several investigator-led clinical studies Quoin is planning for QRX009 across multiple indications.
- Undisclosed Canadian PartnerminorCommercialization agreement signed for Canadian market in July 2022.
- Undisclosed Greater China PartnerminorDistribution agreement covering Greater China signed June 2022.
- Queensland University of Technology (QUT)coreSecond exclusive research agreement with QUT (May 2022) for scleroderma treatment. Additionally, a funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT.
- Undisclosed Middle East / North Africa / Australasia PartnersminorExclusive distribution agreements signed covering the Middle East, North Africa, and Australasia in November 2021.
- Undisclosed Israel and European PartnersminorMarketing partnerships for distribution of QRX003 in Israel and to 21 European countries signed February 2022.
- Undisclosed Latin America PartnerminorExclusive distribution agreement for key Latin America markets signed January 2022 as part of international expansion covering 61 countries.
- University College Cork (UCC)coreQuoin signed a research agreement with University College Cork in Ireland in June 2024 to support the scleroderma treatment program (QRX008). Additionally, an earlier funding agreement (November 2021) supported preclinical investigation of a bi-functional protein at QUT. CEO Dr. Michael Myers earned his Ph.D. in Chemistry from University College Cork.
- AFT PharmaceuticalscoreDistribution partner covering Australasia region as part of nine separate strategic commercial agreements spanning 61 countries.
- WinHealthminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- Er-KimminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- NeopharmminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- GenPharmminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- OrPharm DCminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- OrPharmminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
- Endo PharmaceuticalsminorDistribution partner (logo shown on company website) as part of nine strategic commercial agreements spanning 61 countries.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
Quoin Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- AnaptysBio: Clinical-stage immunology company developing therapeutics for inflammatory diseases. Comparable in immunology/inflammation mechanism focus, though broader therapeutic area beyond dermatology.
- Castle Creek Biosciences: Late clinical-stage biotech developing therapies for rare genetic dermatological diseases including epidermolysis bullosa. Direct overlap in rare skin disease orphan-drug strategy.
Direct peers
- Aclaris Therapeutics: Clinical-stage dermatology company developing therapeutics for skin diseases including rare immuno-dermatology indications. Similar size and stage profile to Quoin with comparable specialty-pharma GTM.
- Arcutis Biotherapeutics: Specialty dermatology pharmaceutical company developing topical treatments for inflammatory skin diseases. Comparable in therapeutic area (medical dermatology), topical delivery focus, and rare/orphan indications.
- Krystal Biotech: Commercial-stage rare-disease dermatology biotech whose lead product Vyjuvek treats dystrophic epidermolysis bullosa. Closest analog to Quoin: rare genetic skin disease, topical/biologics platform, multi-jurisdiction orphan strategy, small public-company scale.
- Sol-Gel Technologies: Specialty dermatology company with FDA-approved topical products for skin conditions including rare indications. Comparable business model: small-cap, focused on topical treatments for dermatological diseases.
- Dermavant Sciences: Dermatology-focused biopharma developing topical therapeutics for skin diseases. Comparable in topical-dermatology development focus and orphan/specialty positioning.
- Amryt Pharma: Previously independent rare-disease dermatology company (acquired by Chiesi in 2023) focused on epidermolysis bullosa and other rare skin conditions. Direct peer pre-acquisition in rare dermatology orphan-drug commercial strategy.
Broad incumbents
- BridgeBio Pharma: Larger rare-disease-focused biopharma with multiple programs across genetic conditions. Less directly comparable as a broader portfolio player, but operates in the same orphan-disease commercial and regulatory paradigm.
- BioMarin Pharmaceutical: Established rare-disease biopharma with multiple approved orphan drugs across genetic conditions. Much larger scale but exemplifies the commercial model Quoin is targeting in Netherton Syndrome.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Quoin Pharmaceuticals social profiles
Digital presenceQuoin Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Quoin Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles11 records
Quoin Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
Quoin Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds7 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Quoin Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Quoin Pharmaceuticals
What does Quoin Pharmaceuticals do?
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing topical and small-molecule therapeutics for rare and orphan skin and connective tissue diseases. Its lead candidate QRX003 (QYLEKI) is a broad-spectrum serine protease inhibitor lotion in pivotal Phase 3 trials for Netherton Syndrome, with additional development in Peeling Skin Syndrome, SAM Syndrome, and Ichthyosis. The pipeline also includes QRX008 (a VLA-4 small-molecule inhibitor for Scleroderma) and QRX009 (a proprietary topical rapamycin lotion and dermal patch for vascular malformations and related skin disorders). None of these products are yet approved; commercial revenue is expected from future product sales supported by a mix of direct sales infrastructure and international distribution partnerships.
Is Quoin Pharmaceuticals a public or private company?
Quoin Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Quoin Pharmaceuticals founded?
Quoin Pharmaceuticals was founded in 2021. It employs 11 to 50 people.
Where is Quoin Pharmaceuticals based?
Quoin Pharmaceuticals is headquartered in Ashburn, United States, in the North America region.
How does Quoin Pharmaceuticals make money?
One revenue line is on record: product Sales (Future).
Who are Quoin Pharmaceuticals's main competitors?
Emerging players on record are AnaptysBio and Castle Creek Biosciences. Direct peers are Aclaris Therapeutics, Arcutis Biotherapeutics, Krystal Biotech, Sol-Gel Technologies, Dermavant Sciences and Amryt Pharma. Broad incumbents are BridgeBio Pharma and BioMarin Pharmaceutical.
Does Quoin Pharmaceuticals have an API?
No public API is recorded for Quoin Pharmaceuticals.
What industry is Quoin Pharmaceuticals in?
Quoin Pharmaceuticals's product category is Specialty Pharmaceuticals — Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 325412 and its SIC code is 2834.